Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma
- Citation:
- Cancer Chemother Pharmacol vol 75 (3) 629-638
- Year:
- 2015
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- William D. Tap and Gary K. Schwartz have been contributed equally to this work.
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 4
- Parents:
- 2141
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Experimental
- Sec. Committees:
- Pharmas:
- Grants:
- U10 CA180821, U10 CA180833, U10 CA180882
- Corr. Author:
- Sandra P. D'Angelo
- Authors:
- Sandra P. D'Angelo Michelle R. Mahoney Brian A. Van Tine Douglas R. Adkins Maria T. Grosse Perdekamp Mercedes M. Condy Jason J. Luke Eliza Woodward Hartley Cristina R. Antonescu William D. Tap Gary K. Schwartz
- Networks:
- COLUMBIA, LAPS-MN026, LAPS-MO011, LAPS-NY016, LAPS-PA015
- Study
- Alliance-A091103
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Angiosarcoma, Trebananib, Angiopoietin system